EP0223842A4 - Monoclonal antibody to decay accelerating factor (daf), a method for making it, and use. - Google Patents

Monoclonal antibody to decay accelerating factor (daf), a method for making it, and use.

Info

Publication number
EP0223842A4
EP0223842A4 EP19860903931 EP86903931A EP0223842A4 EP 0223842 A4 EP0223842 A4 EP 0223842A4 EP 19860903931 EP19860903931 EP 19860903931 EP 86903931 A EP86903931 A EP 86903931A EP 0223842 A4 EP0223842 A4 EP 0223842A4
Authority
EP
European Patent Office
Prior art keywords
daf
making
monoclonal antibody
accelerating factor
decay accelerating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19860903931
Other languages
German (de)
French (fr)
Other versions
EP0223842A1 (en
Inventor
Taroh Kinoshita
M Edward Medof
Victor Nussenzweig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Publication of EP0223842A1 publication Critical patent/EP0223842A1/en
Publication of EP0223842A4 publication Critical patent/EP0223842A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP19860903931 1985-05-24 1986-05-23 Monoclonal antibody to decay accelerating factor (daf), a method for making it, and use. Withdrawn EP0223842A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73817185A 1985-05-24 1985-05-24
US738171 1985-05-24

Publications (2)

Publication Number Publication Date
EP0223842A1 EP0223842A1 (en) 1987-06-03
EP0223842A4 true EP0223842A4 (en) 1987-08-24

Family

ID=24966867

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860903931 Withdrawn EP0223842A4 (en) 1985-05-24 1986-05-23 Monoclonal antibody to decay accelerating factor (daf), a method for making it, and use.

Country Status (3)

Country Link
EP (1) EP0223842A4 (en)
JP (1) JPS63500797A (en)
WO (1) WO1986007062A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US5264357A (en) * 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
JP3562834B2 (en) * 1994-06-01 2004-09-08 孝夫 辻 Test method for DAF molecules in stool
EP1157041B1 (en) * 1999-03-01 2005-06-01 Genentech, Inc. Antibodies for cancer therapy and diagnosis
EP1591456A1 (en) * 1999-03-01 2005-11-02 Genentech Inc. Antibodies for cancer therapy and diagnosis
FR3080181B1 (en) 2018-04-12 2020-03-20 Sartorius Stedim Fmt Sas METHOD AND DEVICE FOR CONTROLLING THE INTEGRITY OF A POCKET FOR BIOPHARMACEUTICAL FLUID
FR3080182B1 (en) 2018-04-12 2020-03-20 Sartorius Stedim Fmt Sas METHOD AND DEVICE FOR CONTROLLING THE INTEGRITY OF A POCKET FOR BIOPHARMACEUTICAL FLUID

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No relevant documents have been disclosed. *
See also references of WO8607062A1 *

Also Published As

Publication number Publication date
WO1986007062A1 (en) 1986-12-04
JPS63500797A (en) 1988-03-24
EP0223842A1 (en) 1987-06-03

Similar Documents

Publication Publication Date Title
RO100383A2 (en) Method to obtain a monoclonal antibody
ZA852438B (en) Antibodies,manufacture and use
HUT38391A (en) Process for preparing new monoclonal antibodies against glycoconjugates and for the utilization thereof
GB8624899D0 (en) Monoclonal antibodies
GB8426463D0 (en) Monoclonal antibodies
GB8422650D0 (en) Monoclonal antibodies
EP0223842A4 (en) Monoclonal antibody to decay accelerating factor (daf), a method for making it, and use.
EP0171083A3 (en) Monoclonal antibody, process for preparing same, reagent for detecting cancer antigen containing the monoclonal antibody and process for preparing same
EP0203967A4 (en) Onco-fetal specific monoclonal antibodies, methods of preparation and use.
EP0147848A3 (en) Method for the determination of a polyvalent antigen, and reagent therefor
GB8530829D0 (en) Monoclonal antibodies
IL77990A (en) Monoclonal anti-alpha-amylase antibody,process for obtaining the same and pharmaceutical compositions containing the same
PT79896A (en) Monoclonal antibody
EP0124548A4 (en) Babesiosis antigen and method for preparation.
GB8517895D0 (en) Monoclonal antibodies
GB8616174D0 (en) Monoclonal antibodies
EP0218587A4 (en) Monoclonal antibodies and method of immunizing therewith.
GB8426461D0 (en) Monoclonal antibodies
HUT37603A (en) Process for producing spiroindenes and spiro-1,2-di-hydronaphtalines
AU5965086A (en) Monoclonal antibody to decay accelerating factor (DAF), a method for making it, and use
GB8426468D0 (en) Monoclonal antibodies
GB8426470D0 (en) Monoclonal antibodies
GB8426459D0 (en) Monoclonal antibodies
GB8610203D0 (en) Monoclonal antibodies
GB8610202D0 (en) Monoclonal antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19870604

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KINOSHITA, TAROH

Inventor name: NUSSENZWEIG, VICTOR

Inventor name: MEDOF, M., EDWARD

A4 Supplementary search report drawn up and despatched

Effective date: 19870824

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MEDOF, M., EDWARD

Inventor name: KINOSHITA, TAROH OSAKA UNIVERSIT MEDICAL SCHOOL

Inventor name: NUSSENZWEIG, VICTOR

17Q First examination report despatched

Effective date: 19890502

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19900113

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NUSSENZWEIG, VICTOR

Inventor name: MEDOF, M., EDWARD

Inventor name: KINOSHITA, TAROHOSAKA UNIVERSITY MEDICAL SCHOOL